Endocrine Abstracts

Objective: Prospective observational study in a group of pregnant patients affected by type 1 diabetes (T1DM), that are monitored by the Endocrinology and Pregnancy Unit.

Material and Methods: Weevaluated 12 pregnant patients with T1DM in which a FreeStyle Libre Flash Glucose Monitoring Systemwas installed, in addition to their capillary glucose self-control (SMBG), over the past year 2019. Time above range (TAR), time in range (TIR) and time below range (TBR) were measured, and all data captured by the sensor, like daily readings, as well as capillary glycosylated hemoglobin, fetal biometrics and birth data, among others.

Results: The mean age of the patients was 31.58 ± s.d. 5.48 years. The mean time of evolution of his T1DM was 10.7 years ± s.d. 10.31. 75% had not planned their gestation. The treatment in 83% of the patients was basal-bolus therapy and 17% ISCI (Medtronic 640 G). The mean pregestational glycosylated hemoglobin was 7.69% ± s.d. 1.73. The mean pre-installation glycosylated hemoglobin was 6.9% ± s.d. 0.9. The mean post-installation was 6.2% ± s.d. 0.86. Visits were scheduled every 4 weeks. The data covering the 14 days prior to the first medical review since the installation of the sensor were the following: average glucose 128.75 ± s.d. 27.32 mg. The time above the target (blood glucose >140 mg) was 21.92% ± s.d. 22.11, the time on target (70–130 mg) was 57.17% ± s.d. 28.29, the time below The target (<70 mg) was 15.08% ± s.d. 10.63. The mean low glucose events was 12.14 ± s.d. 7.64, with an average duration of 125 ± s.d. 26.65 minutes. The average of data collected by the sensor of the patients was 90.80% ± s.d. 9.63, as well as readings of 8.56 ± s.d. 5.17. Fetal ultrasound was consistent with gestational age in 100% of pregnant women during their follow-up. Childbirth occurred in 50% of patients during the year 2019. The average weight of the newborn was 3191.50 ± s.d. 136.02 grs.

Conclusions: FreeStyle Libre Flash Glucose Monitoring Systemcan improve the outcome and quality of life in pregnant patients affected byT1DM, however, the evidence to support its use in pregnant women is limited. Studies with more patients are needed to determine if sensor measurements can completely replace theblood glucose self-controls (SMBG).